Safety alerts in EMRs reduce rates of potentially dangerous drug interactions


The results of the Safety in Prescribing study, conducted by Kaiser Permanente’s Center for Health Research, showed that electronic medication alerts reduce inappropriate prescribing of Warfarin with interacting drugs.

The study is published in the Archives of Internal Medicine.

“ This study shows that safety alerts in electronic medical records ( EMRs ) are a powerful tool to help clinicians make decisions about what drugs they should prescribe for their patients,” says Adrianne Feldstein, lead author of the study and an investigator at Kaiser Permanente’s Center for Health Research. “ We compared the effects of two interventions in outpatient clinical settings – safety alerts in EMRs versus safety alerts plus clinician education courses. We found that adding clinician education to EMR safety alerts did not reduce the rates of co-prescribing medications that interact any more than EMR safety alerts alone. The reason is unclear, but it may be that the “just in time” information provided by safety alerts is more useful to clinicians than education courses.”

The study focused on patients who were prescribed Warfarin, an anticoagulant.
Warfarin is prescribed to patients with blood clots in the lower extremities; patients with atrial fibrillation, artificial heart valves, and coronary artery stents; and patients who have knee or hip replacements. It was chosen for the study because it is widely used – over one million prescriptions annually – and because so many drugs – prescription and non-prescription – interact with Warfarin to increase its blood-thinning effects. Results of a report from a large pharmacy benefits manager database show that more than two-thirds of patients receiving Warfarin during a one-year period received at least one interacting medication that increased bleeding risk.

To conduct the study, the researchers tracked the co-prescribing rates of clinicians at 15 primary care clinics before the alerts from January 2000 through November 2002. They analyzed the electronic medical records of 9910 patients taking Warfarin to find out the prescription rates of Warfarin and five interacting medications – Acetaminophen ( Paracetamol ), non-steroidal anti-inflammatory drugs ( NSAIDs ), Fluconazole, Metronidazole, and Sulfamethoxasole.
During a four-month period from December 2002 to March 2003, safety alerts were randomly implemented in eight clinics, and safety alerts and education courses were implemented in the other seven clinics. The safety alerts remained active in all 15 clinics for 18 months from April 2003 through August 2004.

In the 12 months prior to the alerts, Warfarin patients received 3,288 interacting prescriptions for every 10,000 Warfarin patients. Interacting prescriptions for Warfarin patients decreased immediately after the alerts were implemented, with an estimated drop in the first month of 329.7 interacting prescriptions for every 10,000 Warfarin patients. Twelve months after the alerts were implemented, Warfarin patients received 2804.2 interacting prescriptions for every 10,000 warfarin users. Compared to an co-prescription without safety alerts estimated at 3294.0, the alerts led to an estimated reduction of 489.8 interacting prescriptions for every 10,000 Warfarin patients, a 14.9% relative reduction. The effect was predominantly due to reductions in the co-prescribing of Warfarin and Acetaminophen.

“ Clinicians face difficult choices when ordering prescription drugs for Warfarin patients,” Feldstein says. “ Because so many drugs interact with Warfarin and have the potential for harm, ideal choices are seldom available. For example, if a Warfarin patient is having a lot of pain, should the clinician prescribe Acetaminophen – which can cause excessive bleeding – or should the clinician prescribe Codeine – which can cause drowsiness and could lead to an older patient tripping or falling and breaking a hip ? There is not always an easy answer. What safety alerts do is help clinicians make these difficult decisions by alerting them about the known interactions among the medications they’ve entered into the electronic medical record and by indicating alternative medications they might prescribe.”

Source: Kaiser Permanente, 2006


XagenaMedicine2006